ClinicalTrials.gg
Active, not recruitingNCT03521154LAURAUpdated Aug 4, 2026Results posted

A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)

A Phase 3 interventional study of Osimertinib 80mg/40mg and Placebo Osimertinib 80mg/40mg in Non Small Cell Lung Cancer (Stage III), sponsored by AstraZeneca. Active, not recruiting at 118 sites in 17 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-08-04.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
216
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung — 20 open to participants now, 43 under way, 8 of them phase 3. osimertinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
14th of 90
216 · median 51
Started
2018
with 12 others
Phase 3
12 of 90
1 open now
Primary completion
2024-01
later than 6 of 42 live
Registered
37th of 90
by date
Lead sponsor
29 of 90
AstraZeneca

Among the 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung, this one is the 14th largest by enrollment, is one of 13 that started in 2018, is one of 12 in phase 3, reaches primary completion later than 6 of the 42 other live ones, and was the 37th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

20 of the 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung are open now, in 7 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About osimertinib

osimertinib: first FDA approval 2015 (TAGRISSO), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

A global study to assess the efficacy and safety of osimertinib following chemoradiation in patients with stage III unresectable Epidermal Growth Factor Receptor Mutation Positive non-small cell lung cancer

Read the detailed description

This is a phase 3 double-blind, randomized, placebo-controlled, study to assess the efficacy and safety of osimertinib following chemoradiation in patients with stage III unresectable EGFR mutation-positive NSCLC, including the most common EGFR sensitising mutations (Ex19Del and L858R), either alone or in combination with other EGFR mutations. Chemoradiation may have been given either given concurrently or sequentially. Patients whose disease has not progressed following chemoradiation will be randomised within 6 weeks of completion of chemoradiation to receive osimertinib or placebo in a 2:1 ratio, and treatment will be continued until disease progression, unacceptable toxicity or other discontinuation criteria are met. After progression, patients can be unblinded and may receive open-label osimertinib. After the final OS analysis, the study blind will be broken and patients still receiving open-label osimertinib will be supplied with open-label osimertinib by AstraZeneca for as long as their treating physician considers they are deriving clinical benefit.

03

Conditions studied

  • Non Small Cell Lung Cancer (Stage III)

Keywords

  • Phase III
  • Osimertinib
  • Non Small Cell Lung Cancer (Stage III)
  • Unresectable NSCLC
  • EGFR
  • chemoradiation therapy
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female aged at least 18 years.
  2. Patients with documented NSCLC of predominantly non-squamous Pathology who present with locally advanced, unresectable (Stage III) disease (according to Version 8 of the International Association for the Study of Lung Cancer [IASLC] Staging Manual in Thoracic Oncology).
  3. The tumor harbours one of the two common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations, assessed by cobas® EGFR Mutation Test v2 (Roche Diagnostics) or FoundationOne® test in a CLIA certified (USA sites) or an accredited local laboratory (sites outside of the USA) or by central testing (cobas® v2 only).
  4. Patients must have received either concurrent chemoradiation or sequential chemoradiation including at least 2 cycles of platinum based chemotherapy and a total dose of radiation of 60 Gy ±10% (54 to 66 Gy).
  5. Chemoradiation must be completed ≤6 weeks prior to randomization.
  6. Patients must not have had disease progression during or following definitive platinum-based, chemoradiation therapy.
  7. World Health Organization (WHO) performance status of 0 or 1.
  8. >12 weeks at Day 1.
  9. Female patients who are not abstinent (in line with the preferred and usual lifestyle choice) must be using adequate measures, must not be breast feeding, and must have a negative pregnancy test prior to first dose of study drug; or female patients must have an evidence of non-.

Exclusion criteria

Exclusion Criteria

  1. Mixed small cell and non-small cell lung cancer histology
  2. History of interstitial lung disease (ILD) prior to chemoradiation
  3. Symptomatic pneumonitis following chemoradiation
  4. Any unresolved toxicity (CTCAE) > Grade 2 from the prior chemoradiation therapy
  5. Any of the following cardiac criteria:

    • Mean resting interval (QTc) >470 msec, obtained from 3 ECGs
    • Any abnormalities in rhythm, conduction, or morphology of resting
    • Patient with any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval and cause Torsades de Pointes
  6. Inadequate bone marrow reserve or organ function
  7. History of other , except: adequately treated non-melanoma skin cancer or lentigo maligna , curatively treated in-situ cancer, or other solid tumors curatively treated with no evidence of disease for > 5 years following the end of treatment and which, in the opinion of the treating physician, do not have a substantial risk of recurrence of the prior malignancy.
  8. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses; or active infection including , and (HIV).
  9. nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of osimertinib
  10. Prior treatment with any prior chemotherapy, radiation therapy, immunotherapy or agents for NSCLC outside of that received in the definitive setting for Stage III disease (chemotherapy and radiotherapy in SCRT and CCRT regimens is allowed for treatment of Stage III disease).
  11. Prior treatment with EGFR-TKI therapy
  12. Major surgery as defined by the investigator within 4 weeks of the first dose of study drug.
  13. Patients currently receiving (unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be strong inducers of (at least 3 weeks prior to receiving the first dose of study drug).
  14. to MRI, including but not limited to, claustrophobia, pace makers, metal implants, intracranial surgical clips and metal foreign bodies
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
216 participants (actual)

Study arms

  • Experimental
    Osimertinib

    Osimertinib (80mg or 40mg orally, once daily), in accordance with the randomization schedule.

    Drug: Osimertinib 80mg/40mg

  • Placebo comparator
    Placebo Osimertinib

    Matching placebo for Osimertinib (80mg or 40mg orally, once daily), in accordance with the randomization schedule

    Drug: Placebo Osimertinib 80mg/40mg

Interventions

  • DrugOsimertinib 80mg/40mg

    Drug page: Osimertinib

    The initial dose of Osimertinib 80mg once daily can be reduced to 40mg once daily. Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met.

  • DrugPlacebo Osimertinib 80mg/40mg

    The initial dose of Placebo Osimertinib 80mg once daily can be reduced to 40mg once daily. Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) by Blinded Independent Central Review (BICR)

    Time from randomisation until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from randomised therapy or receives another anti-cancer therapy prior to progression, based on BICR assessment according to RECIST v1.1

    Time frame: Every 8 weeks for first 48 weeks, then every 12 weeks until BICR-confirmed radiological disease progression. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months

Secondary outcomes

  1. Number of Participants With Progression-free Survival (PFS) Events in Patients With EGFR Ex19del or L858R Mutation

    Number of PFS events (PFS is time from randomisation until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from randomised therapy or receives another anti-cancer therapy prior to progression, based on BICR assessment according to RECIST v1.1)

    Time frame: Every 8 weeks for first 48 weeks, then every 12 weeks until BICR-confirmed radiological disease progression. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months

  2. Number of Participants With Progression-free Survival (PFS) Events in Patients With EGFR Mutations Ex19del or L858R Detectable in Plasma-derived ctDNA

    Number of PFS events (PFS is time from randomisation until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from randomised therapy or receives another anti-cancer therapy prior to progression, based on blinded independent central review (BICR) assessment according to RECIST v1.1)

    Time frame: Every 8 weeks for first 48 weeks, then every 12 weeks until BICR-confirmed radiological disease progression. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months

  3. Central Nervous System (CNS) Progression-free Survival (PFS) by Blinded Independent Central Review (BICR)

    Time from randomisation until the date of CNS disease progression or death (by any cause in the absence of CNS progression) regardless of whether the patient withdraws from randomised therapy or receives another anti-cancer therapy prior to progression, based on CNS BICR assessment according to RECIST v1.1

    Time frame: Every 8 weeks for first 48 weeks, then every 12 weeks until BICR-confirmed radiological disease progression. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months

  4. Overall Survival (Count)

    Number of patients with Overall Survival (OS), the time from the date of randomisation until date of death by any cause

    Time frame: Date of randomisation to date of death by any cause. Assessed up to a maximum of approximately 63 months

  5. Overall Survival (Duration)

    Time from the date of randomisation until death by any cause

    Time frame: Date of randomisation to date of death by any cause. Assessed up to a maximum of approximately 63 months

  6. Objective Response Rate by Blinded Independent Central Review (BICR)

    Percentage of evaluable patients with at least one BICR assessed visit response of complete response (CR) or partial response (PR). CR defined as disappearance of all target lesions (TL) since baseline. Any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10mm. PR defined as \>= 30% decrease in the sum of diameters of target lesions (compared to baseline sum of diameters). Responses include both confirmed and unconfirmed BICR responses

    Time frame: Every 8 weeks for first 48 weeks, then every 12 weeks until radiological disease progression. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months

  7. Duration of Response, Unconfirmed by Blinded Independent Central Review (BICR)

    Date of PFS event - date of first unconfirmed response + 1 day (and expressed in months) for unconfirmed responses only

    Time frame: Every 8 weeks for first 48 weeks, then every 12 weeks until radiological disease progression. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months

  8. Disease Control Rate by Blinded Independent Central Review (BICR)

    Percentage of patients who have a best overall response of complete response (CR), partial response (PR) or stable disease (SD) as assessed by BICR

    Time frame: Every 8 weeks for first 48 weeks, then every 12 weeks until BICR-confirmed radiological disease progression. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months

  9. Tumour Shrinkage by Blinded Independent Central Review (BICR)

    Depth of response (or tumour shrinkage or change in tumour size) was assessed using BICR responses in target lesions. The best change in tumour size is the largest decrease from baseline or the smallest increase from baseline in the absence of a reduction

    Time frame: Every 8 weeks for first 48 weeks, then every 12 weeks until BICR-confirmed radiological disease progression. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months

  10. Proportion With Tumour Shrinkage by Blinded Independent Central Review (BICR)

    Proportion with depth of response (or tumour shrinkage or change in tumour size)

    Time frame: Every 8 weeks for first 48 weeks, then every 12 weeks until BICR-confirmed radiological disease progression. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months

  11. Time to Death or Distant Metastases by Blinded Independent Central Review (BICR)

    Time from the date of randomisation until the first date of distant metastases or date of death in the absence of distant metastasis. Distant metastasis is defined as any new lesion that is detected on a scan that is anywhere other than lung or regional lymph node according to RECIST v1.1 or proven by biopsy

    Time frame: Time from randomisation to the date of distant metastases or death. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months

  12. Time to Study Treatment Discontinuation

    Time from randomisation to the earlier of the date of study treatment discontinuation (regardless of the reason for study treatment discontinuation) or death (i.e. date of study treatment discontinuation/death or censoring - date of randomisation + 1 day, expressed in months)

    Time frame: Time from randomisation to the earlier of the date of study treatment discontinuation or death. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months

  13. Time to First Subsequent Treatment

    Time from the date of randomisation to the earlier of the date of anti-cancer therapy start date following study drug discontinuation or death

    Time frame: Time from randomisation to the start of first subsequent anti-cancer therapy or death. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months

  14. Time to Second Subsequent Treatment

    Time from the date of randomisation to the earlier of the second subsequent anti-cancer therapy start date following study drug discontinuation or death

    Time frame: Time from randomisation to the start of second subsequent anti-cancer therapy or death. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months

  15. Second Progression-free Survival (PFS2)

    Time from randomisation to the earliest progression event following first objective disease progression, subsequent to the first subsequent therapy, or death.

    Time frame: Every 8 weeks for first 48 weeks, then every 12 weeks. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months

07

Results

Posted Apr 3, 2025
Limitations and caveats
As per CSP Section 7.2, patient monitoring during treatment with open-label osimertinib is monitored by the investigator per local clinical guidance. Serious AEs and AESIs are reported in the eCRF but were not analyzed/tabulated at the time of primary analysis. Safety assessments are to be performed as per local clinical practice and not collected as part of study data capture in line with the protocol.

Participant flow

Participant flow — Overall Study
MilestoneOsimertinibPlacebo
Started14373
Completed3221
Not completed11152
Withdrew: Ongoing study at data cut-off11152

Outcome measures

PrimaryProgression-free Survival (PFS) by Blinded Independent Central Review (BICR)

Time from randomisation until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from randomised therapy or receives another anti-cancer therapy prior to progression, based on BICR assessment according to RECIST v1.1

Time frame:
Every 8 weeks for first 48 weeks, then every 12 weeks until BICR-confirmed radiological disease progression. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months
Reported as:
Median · Months
Progression-free Survival (PFS) by Blinded Independent Central Review (BICR)
MonthsOsimertinibPlacebo
Progression-free Survival (PFS) by Blinded Independent Central Review (BICR)39.13 (31.51 to NA)5.55 (3.71 to 7.43)
Statistical analysis
  • Osimertinib vs Placebo · Log Rank · p = <0.001 · Hazard ratio (hr): 0.16 · 95% CI 0.10 to 0.24A hazard ratio \< 1 favours osimertinib
SecondaryNumber of Participants With Progression-free Survival (PFS) Events in Patients With EGFR Ex19del or L858R Mutation

Number of PFS events (PFS is time from randomisation until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from randomised therapy or receives another anti-cancer therapy prior to progression, based on BICR assessment according to RECIST v1.1)

Time frame:
Every 8 weeks for first 48 weeks, then every 12 weeks until BICR-confirmed radiological disease progression. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months
Reported as:
Count of participants · Participants
Number of Participants With Progression-free Survival (PFS) Events in Patients With EGFR Ex19del or L858R Mutation
ParticipantsOsimertinibPlacebo
Ex19Del positive2639
L858R positive3124
Missing00
Statistical analysis
  • Osimertinib vs Placebo · Cox proportional hazard model · Hazard ratio (hr): 0.17 · 95% CI 0.10 to 0.29A hazard ratio \< 1 favours osimertinib
  • Osimertinib vs Placebo · Cox proportional hazard model · Hazard ratio (hr): 0.32 · 95% CI 0.19 to 0.56A hazard ratio \< 1 favours osimertinib
SecondaryNumber of Participants With Progression-free Survival (PFS) Events in Patients With EGFR Mutations Ex19del or L858R Detectable in Plasma-derived ctDNA

Number of PFS events (PFS is time from randomisation until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from randomised therapy or receives another anti-cancer therapy prior to progression, based on blinded independent central review (BICR) assessment according to RECIST v1.1)

Time frame:
Every 8 weeks for first 48 weeks, then every 12 weeks until BICR-confirmed radiological disease progression. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months
Reported as:
Count of participants · Participants
Number of Participants With Progression-free Survival (PFS) Events in Patients With EGFR Mutations Ex19del or L858R Detectable in Plasma-derived ctDNA
ParticipantsOsimertinibPlacebo
EGFR mutation-positive44
EGFR mutation-negative4251
EGFR mutation-unknown118
Statistical analysis
  • Osimertinib vs Placebo · Cox proportional hazard model · Hazard ratio (hr): 0.22 · 95% CI 0.15 to 0.34A hazard ratio \< 1 favours osimertinib
SecondaryCentral Nervous System (CNS) Progression-free Survival (PFS) by Blinded Independent Central Review (BICR)

Time from randomisation until the date of CNS disease progression or death (by any cause in the absence of CNS progression) regardless of whether the patient withdraws from randomised therapy or receives another anti-cancer therapy prior to progression, based on CNS BICR assessment according to RECIST v1.1

Time frame:
Every 8 weeks for first 48 weeks, then every 12 weeks until BICR-confirmed radiological disease progression. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months
Reported as:
Median · Months
Central Nervous System (CNS) Progression-free Survival (PFS) by Blinded Independent Central Review (BICR)
MonthsOsimertinibPlacebo
Central Nervous System (CNS) Progression-free Survival (PFS) by Blinded Independent Central Review (BICR)NA (NA to NA)14.88 (7.36 to NA)
Statistical analysis
  • Osimertinib vs Placebo · Log Rank · p = <0.001 · Hazard ratio (hr): 0.17 · 95% CI 0.09 to 0.32A hazard ratio \< 1 favours osimertinib
SecondaryOverall Survival (Count)

Number of patients with Overall Survival (OS), the time from the date of randomisation until date of death by any cause

Time frame:
Date of randomisation to date of death by any cause. Assessed up to a maximum of approximately 63 months
Reported as:
Count of participants · Participants
Overall Survival (Count)
ParticipantsOsimertinibPlacebo
Died2815
Censored (includes participants still in survival follow up and terminated prior to death)11558
SecondaryOverall Survival (Duration)

Time from the date of randomisation until death by any cause

Time frame:
Date of randomisation to date of death by any cause. Assessed up to a maximum of approximately 63 months
Reported as:
Median · Months
Overall Survival (Duration)
MonthsOsimertinibPlacebo
Overall Survival (Duration)53.95 (46.49 to NA)NA (42.05 to NA)
Statistical analysis
  • Osimertinib vs Placebo · Log Rank · p = 0.530 · Hazard ratio (hr): 0.81 · 95% CI 0.42 to 1.56A hazard ratio \< 1 favours osimertinib
SecondaryObjective Response Rate by Blinded Independent Central Review (BICR)

Percentage of evaluable patients with at least one BICR assessed visit response of complete response (CR) or partial response (PR). CR defined as disappearance of all target lesions (TL) since baseline. Any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10mm. PR defined as \>= 30% decrease in the sum of diameters of target lesions (compared to baseline sum of diameters). Responses include both confirmed and unconfirmed BICR responses

Time frame:
Every 8 weeks for first 48 weeks, then every 12 weeks until radiological disease progression. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months
Reported as:
Number · % of participants
Objective Response Rate by Blinded Independent Central Review (BICR)
% of participantsOsimertinibPlacebo
Objective Response Rate by Blinded Independent Central Review (BICR)57.3 (48.8 to 65.6)32.9 (22.3 to 44.9)
Statistical analysis
  • Osimertinib vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 2.77 · 95% CI 1.54 to 5.08An odds ratio \> 1 favours osimertinib
SecondaryDuration of Response, Unconfirmed by Blinded Independent Central Review (BICR)

Date of PFS event - date of first unconfirmed response + 1 day (and expressed in months) for unconfirmed responses only

Time frame:
Every 8 weeks for first 48 weeks, then every 12 weeks until radiological disease progression. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months
Reported as:
Median · Months
Duration of Response, Unconfirmed by Blinded Independent Central Review (BICR)
MonthsOsimertinibPlacebo
Duration of Response, Unconfirmed by Blinded Independent Central Review (BICR)36.9 (17.9 to NA)6.5 (3.2 to 9.0)
SecondaryDisease Control Rate by Blinded Independent Central Review (BICR)

Percentage of patients who have a best overall response of complete response (CR), partial response (PR) or stable disease (SD) as assessed by BICR

Time frame:
Every 8 weeks for first 48 weeks, then every 12 weeks until BICR-confirmed radiological disease progression. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months
Reported as:
Number · % of participants
Disease Control Rate by Blinded Independent Central Review (BICR)
% of participantsOsimertinibPlacebo
Disease Control Rate by Blinded Independent Central Review (BICR)88.8 (82.5 to 93.5)79.5 (68.4 to 88.0)
Statistical analysis
  • Osimertinib vs Placebo · Regression, Logistic · p = 0.069 · Odds ratio (or): 2.06 · 95% CI 0.94 to 4.47An odds ratio \> 1 favours osimertinib.
SecondaryTumour Shrinkage by Blinded Independent Central Review (BICR)

Depth of response (or tumour shrinkage or change in tumour size) was assessed using BICR responses in target lesions. The best change in tumour size is the largest decrease from baseline or the smallest increase from baseline in the absence of a reduction

Time frame:
Every 8 weeks for first 48 weeks, then every 12 weeks until BICR-confirmed radiological disease progression. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months
Reported as:
Median · % change from baseline
Tumour Shrinkage by Blinded Independent Central Review (BICR)
% change from baselineOsimertinibPlacebo
Tumour Shrinkage by Blinded Independent Central Review (BICR)-43.3 (-100 to 144)-21.9 (-100 to 23)
SecondaryProportion With Tumour Shrinkage by Blinded Independent Central Review (BICR)

Proportion with depth of response (or tumour shrinkage or change in tumour size)

Time frame:
Every 8 weeks for first 48 weeks, then every 12 weeks until BICR-confirmed radiological disease progression. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months
Reported as:
Number · Proportion of participants
Proportion With Tumour Shrinkage by Blinded Independent Central Review (BICR)
Proportion of participantsOsimertinibPlacebo
Proportion with reduction0.920.83
Proportion with reduction > 30%0.650.40
Proportion with reduction > 50%0.430.11
Proportion with reduction > 75%0.180.09
SecondaryTime to Death or Distant Metastases by Blinded Independent Central Review (BICR)

Time from the date of randomisation until the first date of distant metastases or date of death in the absence of distant metastasis. Distant metastasis is defined as any new lesion that is detected on a scan that is anywhere other than lung or regional lymph node according to RECIST v1.1 or proven by biopsy

Time frame:
Time from randomisation to the date of distant metastases or death. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months
Reported as:
Median · Months
Time to Death or Distant Metastases by Blinded Independent Central Review (BICR)
MonthsOsimertinibPlacebo
Time to Death or Distant Metastases by Blinded Independent Central Review (BICR)NA (39.29 to NA)13.04 (9.03 to NA)
Statistical analysis
  • Osimertinib vs Placebo · Log Rank · p = <0.001 · Hazard ratio (hr): 0.21 · 95% CI 0.11 to 0.38A hazard ratio \< 1 favours osimertinib
SecondaryTime to Study Treatment Discontinuation

Time from randomisation to the earlier of the date of study treatment discontinuation (regardless of the reason for study treatment discontinuation) or death (i.e. date of study treatment discontinuation/death or censoring - date of randomisation + 1 day, expressed in months)

Time frame:
Time from randomisation to the earlier of the date of study treatment discontinuation or death. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months
Reported as:
Median · Months
Time to Study Treatment Discontinuation
MonthsOsimertinibPlacebo
Time to Study Treatment Discontinuation40.28 (32.72 to NA)8.31 (6.14 to 11.10)
Statistical analysis
  • Osimertinib vs Placebo · Log Rank · p = <0.001 · Hazard ratio (hr): 0.21 · 95% CI 0.14 to 0.32A hazard ratio \< 1 favours osimertinib
SecondaryTime to First Subsequent Treatment

Time from the date of randomisation to the earlier of the date of anti-cancer therapy start date following study drug discontinuation or death

Time frame:
Time from randomisation to the start of first subsequent anti-cancer therapy or death. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months
Reported as:
Median · Months
Time to First Subsequent Treatment
MonthsOsimertinibPlacebo
Time to First Subsequent Treatment43.83 (38.87 to NA)9.46 (6.60 to 11.53)
Statistical analysis
  • Osimertinib vs Placebo · Log Rank · p = <0.001 · Hazard ratio (hr): 0.13 · 95% CI 0.08 to 0.21A hazard ratio \< 1 favours osimertinib
SecondaryTime to Second Subsequent Treatment

Time from the date of randomisation to the earlier of the second subsequent anti-cancer therapy start date following study drug discontinuation or death

Time frame:
Time from randomisation to the start of second subsequent anti-cancer therapy or death. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months
Reported as:
Median · Months
Time to Second Subsequent Treatment
MonthsOsimertinibPlacebo
Time to Second Subsequent TreatmentNA (44.42 to NA)47.38 (34.14 to NA)
Statistical analysis
  • Osimertinib vs Placebo · Log Rank · p = 0.022 · Hazard ratio (hr): 0.51 · 95% CI 0.28 to 0.91A hazard ratio \< 1 favours osimertinib
SecondarySecond Progression-free Survival (PFS2)

Time from randomisation to the earliest progression event following first objective disease progression, subsequent to the first subsequent therapy, or death.

Time frame:
Every 8 weeks for first 48 weeks, then every 12 weeks. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months
Reported as:
Median · Months
Second Progression-free Survival (PFS2)
MonthsOsimertinibPlacebo
Second Progression-free Survival (PFS2)48.20 (44.42 to NA)47.38 (28.22 to NA)
Statistical analysis
  • Osimertinib vs Placebo · Log Rank · p = 0.088 · Hazard ratio (hr): 0.62 · 95% CI 0.35 to 1.08A hazard ratio \< 1 favours osimertinib

Adverse events

Collected over From the time of signature of informed consent throughout the treatment period (maximum actual duration of 62.4 and 56.2 months for Osimertinib and Placebo respectively) up to and including 28 day follow up following last dose of study drug.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Osimertinib28/143 (19.6%)55/143 (38.5%)129/143 (90.2%)
Placebo15/73 (20.5%)11/73 (15.1%)54/73 (74%)
Most frequent serious events
Showing 10 of 47
Most frequent serious events
EventOsimertinibPlacebo
Radiation pneumonitisInjury, poisoning and procedural complications15/1432/73
PneumoniaInfections and infestations7/1433/73
GastroenteritisInfections and infestations2/1430/73
PneumonitisRespiratory, thoracic and mediastinal disorders2/1430/73
NauseaGastrointestinal disorders0/1431/73
MalaiseGeneral disorders0/1431/73
Pneumonia aspirationInfections and infestations0/1431/73
Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1431/73
Cerebrovascular accidentNervous system disorders0/1431/73
Myocardial infarctionCardiac disorders0/1431/73
Most frequent other events
Showing 10 of 28
Most frequent other events
EventOsimertinibPlacebo
Radiation pneumonitisInjury, poisoning and procedural complications55/14326/73
DiarrhoeaGastrointestinal disorders51/14310/73
RashSkin and subcutaneous tissue disorders34/14310/73
Covid-19Infections and infestations28/1436/73
ParonychiaInfections and infestations24/1431/73
CoughRespiratory, thoracic and mediastinal disorders23/1437/73
Decreased appetiteMetabolism and nutrition disorders21/1434/73
Dry skinSkin and subcutaneous tissue disorders18/1434/73
PruritusSkin and subcutaneous tissue disorders18/1435/73
Musculoskeletal chest painMusculoskeletal and connective tissue disorders5/1439/73

Baseline characteristics

Age, Continuous
Age, Continuous(Years)OsimertinibPlaceboTotal
Median62 (36 to 84)64 (37 to 83)62.5 (36 to 84)
Sex: Female, Male
Sex: Female, Male(Participants)OsimertinibPlaceboTotal
Female9042132
Male533184
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)OsimertinibPlaceboTotal
Hispanic or Latino11213
Not Hispanic or Latino13271203
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)OsimertinibPlaceboTotal
American Indian or Alaska Native213
Asian11662178
Native Hawaiian or Other Pacific Islander000
Black or African American000
White201030
More than one race000
Unknown or Not Reported505
08

Study locations

118 sites
  • Research Site
    Duarte, California 91010, United States
  • Research Site
    Atlanta, Georgia 30322, United States
  • Research Site
    Florham Park, New Jersey 07932, United States
  • Research Site
    Salt Lake City, Utah 84106, United States
  • Research Site
    Madison, Wisconsin 53792, United States
  • Research Site
    Ciudad Autónoma de Bs. As., 1426, Argentina
  • Research Site
    Ciudad Autónoma de Bs. As., C1199ABB, Argentina
  • Research Site
    Mar del Plata, 7600, Argentina
  • Research Site
    Rosario, 2000, Argentina
  • Research Site
    San Salvador de Jujuy, 4600, Argentina
  • Research Site
    Barretos, 14784-400, Brazil
  • Research Site
    Curitiba, 81520-060, Brazil
  • Research Site
    Florianópolis, 88034-000, Brazil
  • Research Site
    Fortaleza, 60336-045, Brazil
  • Research Site
    Porto Alegre, 90160-093, Brazil
  • Research Site
    Porto Alegre, 90610-000, Brazil
  • Research Site
    Ribeirão Preto, 14021-636, Brazil
  • Research Site
    São Paulo, 01221-0100, Brazil
  • Research Site
    São Paulo, 01246-000, Brazil
  • Research Site
    Beijing, 100021, China
  • Research Site
    Beijing, 100730, China
  • Research Site
    Changchun, 130000, China
  • Research Site
    Changsha, 410013, China
  • Research Site
    Chengdu, 610041, China
  • Research Site
    Guangzhou, 510100, China
  • Research Site
    Hangzhou, 310003, China
  • Research Site
    Hangzhou, 310006, China
  • Research Site
    Hangzhou, 310022, China
  • Research Site
    Jinan, 250117, China
  • Research Site
    Linhai, 317000, China
  • Research Site
    Shanghai, 200030, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Ürümqi, 830099, China
  • Research Site
    Wuhan, 430022, China
  • Research Site
    Wuhan, 430030, China
  • Research Site
    Budapest, 1083, Hungary
  • Research Site
    Budapest, 1121, Hungary
  • Research Site
    Gyöngyös - Mátraháza, 3200, Hungary
  • Research Site
    Pécs, 7623, Hungary
  • Research Site
    Bangalore, 560068, India
  • Research Site
    Gurgaon, 122001, India
  • Research Site
    Hubli, 580025, India
  • Research Site
    Karamsad, 388325, India
  • Research Site
    Kolkata, 700160, India
  • Research Site
    Nashik, 422002, India
  • Research Site
    New Delhi, 110063, India
  • Research Site
    New Delhi, 110085, India
  • Research Site
    New Delhi, 11029, India
  • Research Site
    Hiroshima, 734-8551, Japan
  • Research Site
    Kanazawa, 920-8641, Japan
  • Research Site
    Kashiwa, 227-8577, Japan
  • Research Site
    Nagoya, 460-0001, Japan
  • Research Site
    Niigata, 951-8566, Japan
  • Research Site
    Osaka, 541-8567, Japan
  • Research Site
    Sakaishi, 591-8555, Japan
  • Research Site
    Sapporo, 003-0804, Japan
  • Research Site
    Sayama, 589-8511, Japan
  • Research Site
    Sendai, 981-0914, Japan
  • Research Site
    Shinjuku-ku, 160-0023, Japan
  • Research Site
    Sunto-gun, 411-8777, Japan
  • Research Site
    Yokohama, 241-8515, Japan
  • Research Site
    George Town, 10450, Malaysia
  • Research Site
    Kuala Lumpur, 59100, Malaysia
  • Research Site
    Kuala Selangor, 46050, Malaysia
  • Research Site
    Mérida, 97134, Mexico
  • Research Site
    Lima, LIMA 31, Peru
  • Research Site
    Lima, Lima 32, Peru
  • Research Site
    Lima, LIMA 34, Peru
  • Research Site
    Lima, LIMA 41, Peru
  • Research Site
    San Isidro, 27, Peru
  • Research Site
    Kazan', 420029, Russia
  • Research Site
    Kostroma, 156005, Russia
  • Research Site
    Moscow, 121205, Russia
  • Research Site
    Novisibirsk, 630082, Russia
  • Research Site
    Obninsk, 249036, Russia
  • Research Site
    Saint Petersburg, 197022, Russia
  • Research Site
    Saint Petersburg, 197758, Russia
  • Research Site
    Ufa, 450054, Russia
  • Research Site
    Cheongju-si, 28644, South Korea
  • Research Site
    Incheon, 21565, South Korea
  • Research Site
    Seongnam-si, 13620, South Korea
  • Research Site
    Seoul, 05505, South Korea
  • Research Site
    Seoul, 06351, South Korea
  • Research Site
    Barcelona, 08003, Spain
  • Research Site
    Madrid, 28040, Spain
  • Research Site
    Madrid, 28046, Spain
  • Research Site
    Málaga, 29010, Spain
  • Research Site
    San Sebastián, 20014, Spain
  • Research Site
    Seville, 41009, Spain
  • Research Site
    Valencia, 46009, Spain
  • Research Site
    Kaohsiung City, 83301, Taiwan
  • Research Site
    Taichung, 402, Taiwan
  • Research Site
    Taichung, 40447, Taiwan
  • Research Site
    Taichung, 40705, Taiwan
  • Research Site
    Tainan, 70403, Taiwan
  • Research Site
    Taipei, 10002, Taiwan
  • Research Site
    Taipei, 11217, Taiwan
  • Research Site
    Taoyuan, 00333, Taiwan
  • Research Site
    Bangkok, 10300, Thailand
  • Research Site
    Bangkok, 10330, Thailand

Showing the first 100 of 118 sites across 17 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Kato T, Dong X, Takahashi T, Soparattanapaisarn N, Geater SL, Wang CL, Arriola E, Moiseenko F, Thompson L, Grainger E, Armenteros-Monterroso E, Evans A, Bolanos A, Ramalingam SS, Lu S. Osimertinib after definitive CRT in unresectable stage III EGFR-mutated NSCLC: safety outcomes from the phase III LAURA study. Lung Cancer. 2026 Jun 6;218:109486. doi: 10.1016/j.lungcan.2026.109486. Online ahead of print. PubMed 42296617 ↗
  • Lu S, Kato T, Dong X, Ahn MJ, Quang LV, Soparattanapaisarn N, Inoue T, Wang CL, Huang M, Yang JC, Cobo M, Ozguroglu M, Casarini I, Sriuranpong V, Cronemberger E, Takahashi T, Runglodvatana Y, Chen M, Huang X, Grainger E, Ghiorghiu D, van der Gronde T, Ramalingam SS. A plain language review of results from the LAURA study: osimertinib after chemoradiotherapy for patients with EGFR-mutated non-small cell lung cancer that cannot be removed by surgery. Future Oncol. 2026 May;22(11):1247-1262. doi: 10.1080/14796694.2026.2652543. Epub 2026 Apr 27. PubMed 42037107 ↗
  • Arriola E, Casarini I, Ozguroglu M, Huang M, Takahashi T, Lai X, Goto K, Maneenil K, Lee KH, Cobo M, Valdiviezo N, Evans A, Bolanos A, Huang X, Lai R, Ramalingam SS. Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy. Eur J Cancer. 2026 Jun 3;240:116744. doi: 10.1016/j.ejca.2026.116744. Epub 2026 Apr 12. PubMed 42019226 ↗
  • Murat-Onana ML, Ramalingam SS, Janne PA, Gray JE, Ahn MJ, John T, Yatabe Y, Huang X, Rukazenkov Y, Javey M, Brown H, Li-Sucholeiki X. EGFR mutation testing across the osimertinib clinical program. Lung Cancer. 2025 Jun;204:108549. doi: 10.1016/j.lungcan.2025.108549. Epub 2025 Apr 18. PubMed 40311309 ↗
  • Lu S, Ahn MJ, Reungwetwattana T, Ozguroglu M, Kato T, Yang JC, Huang M, Fujiki F, Inoue T, Quang LV, Sriuranpong V, Vicente D, Fuentes C, Chaudhry AA, Poole L, Armenteros Monterroso E, Rukazenkov Y, van der Gronde T, Ramalingam SS. Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study. Ann Oncol. 2024 Dec;35(12):1116-1125. doi: 10.1016/j.annonc.2024.08.2243. Epub 2024 Sep 16. PubMed 39289145 ↗
  • Lu S, Kato T, Dong X, Ahn MJ, Quang LV, Soparattanapaisarn N, Inoue T, Wang CL, Huang M, Yang JC, Cobo M, Ozguroglu M, Casarini I, Khiem DV, Sriuranpong V, Cronemberger E, Takahashi T, Runglodvatana Y, Chen M, Huang X, Grainger E, Ghiorghiu D, van der Gronde T, Ramalingam SS; LAURA Trial Investigators. Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC. N Engl J Med. 2024 Aug 15;391(7):585-597. doi: 10.1056/NEJMoa2402614. Epub 2024 Jun 2. PubMed 38828946 ↗
  • Tu CY, Hsia TC, Lin YC, Liang JA, Li CC, Chien CR. Efficacy of Definitive Radiotherapy for Patients with Clinical Stage IIIB or IIIC Lung Adenocarcinoma and Epidermal Growth Factor Receptor (EGFR) Mutations Treated Using First- or Second-Generation EGFR Tyrosine Kinase Inhibitors. Can Respir J. 2024 Mar 5;2024:8889536. doi: 10.1155/2024/8889536. eCollection 2024. PubMed 38476120 ↗
  • Lu S, Casarini I, Kato T, Cobo M, Ozguroglu M, Hodge R, van der Gronde T, Saggese M, Ramalingam SS. Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non-small-cell Lung Cancer: LAURA Trial in Progress. Clin Lung Cancer. 2021 Jul;22(4):371-375. doi: 10.1016/j.cllc.2020.11.004. Epub 2021 Jan 6. PubMed 33558193 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in Jan 2024, 65 months.

Results were first posted in Apr 2025, 1 year 2 months after primary completion.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 65 months is above that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2018
First posted
May 11, 2018
StartActual
Jul 19, 2018
Primary completionActual
Jan 5, 2024
CompletionEst.
Oct 29, 2027
Results first posted
Apr 3, 2025
Last update
Aug 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03521154
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
May 11, 2018
Start date
Jul 19, 2018
Primary completion
Jan 5, 2024
Completion
Oct 29, 2027 (estimated)
Results posted
Apr 3, 2025
Last update
Aug 4, 2026

Study contacts

Suresh S Ramalingam, MD
principal investigator · Emory University School of Medicine, Atlanta, U.S.
Shun Lu, MD
principal investigator · Shanghai Chest Hospital, Shanghai, China

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Osimertinib

Start the discussion